Blood pressure lowering

A water-soluble phosphine derivative of diazepam allows for more convenient parenteral tranquilizer therapy and avoids some complications due to blood pressure lowering caused by the propylene glycol medium otherwise required for administration. Fosazepam (82) is prepared from benzodiazepine by sodium hydride-mediated alkylation with chioromethyldimethyl phosphine... 

Patients who are otherwise eligible (except blood pressure) for alteplase, should have their blood pressure lowered cautiously to a systolic <185 mmHg and a diastolic <110 mmHg... 

Drug selection for the management of patients with hypertension should be considered as adjunctive to nonpharmacologic approaches for blood pressure lowering, and ultimately the attainment of target blood pressure in many cases maybe more important than the antihypertensive agent used. 

Often used to augment blood pressure lowering, CCBAs are most commonly used as add-on therapy for patients who are in need of further blood pressure lowering above and beyond that afforded by diuretics or other antihypertensives. Nonetheless, they have demonstrated their efficacy in select patient populations as very effective blood pressure lowering agents. 

Apart from possible clinical differences between the P-block-ers approved for HF, selection of a p-blocker may also be affected by pharmacologic differences. Carvedilol exhibits a more pronounced blood pressure lowering effect and thus causes more frequent dizziness and hypotension as a consequence of its ar receptor blocking activity. Therefore, in patients predisposed to symptomatic hypotension, such as those with advanced LV dysfunction (LVEF less than 20%) who normally exhibit low systolic blood pressures, metoprolol succinate may be the most desirable first-line P-blocker. In patients with uncontrolled hypertension, carvedilol may provide additional antihypertensive efficacy. 

All ACE-I + diuretic or ARB blood pressure lowering Peridopril 2-8 mg daily Indapamide 1.25-5 mg daily Statin therapy ... 

Clonidine Demonstrated efficacy in hot flash reduction in most trials Variety of dose regimens most common 0.1-0.4 mg daily Dry mouth, blood pressure lowering monitor blood pressure... 

Hypertension (systolic blood pressure greater than or equal to 140 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg) or current use of blood-pressure-lowering medication(s)... 

Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) are members of a family of so-called natriuretic peptides, synthesized predominantly in the cardiac atrium, ventricle, and vascular endothelial cells, respectively (G13, Y2). ANP is a 28-amino-acid polypeptide hormone released into the circulation in response to atrial stretch (L3). ANP acts (Fig. 8) on the kidney to increase sodium excretion and glomerular filtration rate (GFR), to antagonize renal vasoconstriction, and to inhibit renin secretion (Ml). In the cardiovascular system, ANP antagonizes vasoconstriction and shifts fluid from the intravascular to the interstitial compartment (G14). In the adrenal cortex, ANP is a powerful inhibitor of aldosterone synthesis (E6, N3). At the hypothalamic level, ANP inhibits vasopressin secretion (S3). It has been shown that some of the effects of ANP are mediated via a newly discovered hormone, called adreno-medullin, controlling fluid and electrolyte homeostasis (S8). The diuretic and blood pressure-lowering effect of ANP may be partially due to adrenomedullin (V5). 

Blood pressure lowering drugs reduce risk of stroke (and myocardial infarction and death) in middle aged patients and even better in the elderly (NNT 86 vs 29 over 5 years) (Pearce 1998). However in the elderly the dysfunction in the autoregulation of brain blood flow, salt and fluids, and increased sensitivity to adverse effects and symptoms may change the picture. 

Now let us go back to methyldopa. The afore-mentioned experiments by HENNING and van ZWIETEN (21) indicated a central mode of action. HEISE and KRONEBERG (22), perfusing part of the third and the entire fourth ventricle of the brain in cats with methyldopa, a-me-thyldopamine and a-methylnoradrenaline were able to show a decrease in blood pressure. These effects were significantly blocked by pretreatment with yohimbine and to a lesser extent by phentolamine. These experiments support the concept of blood pressure lowering by an action on central a-adrenoreceptors. 

Recent experiments carried out by BOLME and coworkers (39) now raise the question of whether the receptors involved in reducing blood pressure are epinephrine receptors or noradrenaline receptors. These workers found that in rats small doses of yohimbine and piper-oxan blocked the blood pressure lowering effect of clonidine, but did not influence the clonidine-induced increase in flexor reflex activity. This effect on the reflex mechanism is possibly mediated by noradrenaline receptors which can be blocked only by higher doses of a-adrenolytic agents. HtfKFELT et al. (40) consider that epinephrine terminals possibly innervate noradrenaline cell bodies at the locus coeruleus. 

---